Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Transdermal Drug Delivery Systems

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Drug Delivery: Miscellaneous Routes

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...

Modified-Release Drug Delivery Systems: Classification

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adolescent Substance Use Disorders.

NEJM evidence·2024

Same author

Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders.

Journal of the American Academy of Child and Adolescent Psychiatry·2022

Same author

Screening for Adolescent Depression and Suicide Risk.

JAMA·2022

Same author

Practice Parameter for the Assessment and Treatment of Psychiatric Disorders in Children and Adolescents With Intellectual Disability (Intellectual Developmental Disorder).

Journal of the American Academy of Child and Adolescent Psychiatry·2021

Same author

Measurement-Based Care in the Treatment of Adolescents with Substance Use Disorders.

Child and adolescent psychiatric clinics of North America·2020

Same author

Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Journal of child and adolescent psychopharmacology·2020

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

Transdermal methylphenidate system: old wine in a new bottle.

Oscar G Bukstein¹

¹Department of Psychiatry, University of Pittsburgh, Western Psychiatric Institute and clinic, School of Medicine, Pittsburgh, PA 15213, USA. buksteinog@upmc.edu

Expert Opinion on Drug Metabolism & Toxicology

|May 16, 2009

Summary

The methylphenidate transdermal system (MTS) patch offers a new way to treat attention-deficit/hyperactivity disorders. It provides similar efficacy and safety to other methylphenidate options, with flexible dosing and less oral intake.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.

Published on: March 17, 2008

Related Experiment Videos

Last Updated: Jun 23, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.

Published on: March 17, 2008

Area of Science:

Pharmacology
Neuroscience
Drug Delivery Systems

Background:

Methylphenidate transdermal system (MTS) is a novel psychostimulant formulation delivered via a skin patch.
Designed for the treatment of attention-deficit/hyperactivity disorders (ADHD).

Purpose of the Study:

To review clinical data supporting the use of the MTS patch.
Evaluate its efficacy, safety, and other relevant considerations.

Main Methods:

Systematic review of clinical studies involving the methylphenidate transdermal system.
Analysis of efficacy, safety, and pharmacokinetic data.

Main Results:

MTS demonstrates comparable efficacy and safety to oral methylphenidate and other stimulants.
Potential for a longer onset of action compared to some formulations.
Transdermal delivery offers flexibility in effect duration.

Conclusions:

The MTS patch is a viable alternative for ADHD treatment, offering benefits in administration and dosing flexibility.
Reduced reliance on oral administration is a key advantage.
Further research may explore optimizing onset time and long-term outcomes.